Daily Stock Analysis, CRIS, Curis Inc, priceseries

Curis Inc. Daily Stock Analysis
Stock Information
Open
2.08
Close
2.07
High
2.15
Low
2.03
Previous Close
2.05
Daily Price Gain
0.02
YTD High
3.38
YTD High Date
Jan 4, 2017
YTD Low
1.60
YTD Low Date
May 22, 2017
YTD Price Change
-1.17
YTD Gain
-36.11%
52 Week High
3.72
52 Week High Date
Nov 15, 2016
52 Week Low
1.56
52 Week Low Date
Jul 25, 2016
52 Week Price Change
0.48
52 Week Gain
30.19%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 20. 2015
1.40
Feb 24. 2015
2.97
24 Trading Days
111.84%
Link
LONG
May 7. 2015
2.74
May 19. 2015
2.90
8 Trading Days
5.93%
Link
LONG
May 26. 2015
3.12
Jun 9. 2015
3.29
10 Trading Days
5.29%
Link
LONG
Nov 20. 2015
2.52
Dec 11. 2015
2.79
14 Trading Days
10.53%
Link
LONG
Mar 1. 2016
1.50
Mar 10. 2016
1.58
7 Trading Days
5.22%
Link
LONG
Apr 11. 2016
1.64
Apr 26. 2016
1.98
11 Trading Days
20.98%
Link
LONG
Sep 15. 2016
1.89
Oct 13. 2016
2.94
20 Trading Days
55.81%
Link
LONG
Nov 7. 2016
2.68
Nov 22. 2016
3.17
11 Trading Days
18.28%
Link
LONG
Dec 16. 2016
2.98
Dec 28. 2016
3.19
7 Trading Days
7.19%
Link
LONG
Mar 8. 2017
2.55
Mar 21. 2017
2.86
9 Trading Days
12.25%
Link
LONG
Jun 16. 2017
1.77
Jun 29. 2017
2.00
9 Trading Days
12.94%
Link
Company Information
Stock Symbol
CRIS
Exchange
NasdaqGM
Company URL
http://www.curis.com
Company Phone
617-503-6500
CEO
Ali Fattaey
Headquarters
Massachusetts
Business Address
4 MAGUIRE ROAD, LEXINGTON, MA 02421
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001108205
About

Curis, Inc. is a biotechnology company, which is focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Its pipeline includes is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase, or HDAC, and phosphatidylinositol-3-kinase, or PI3K enzymes. The company conducts research programs both internally and through strategic collaborations. Curis was founded on February 14, 2000 and is headquartered in Lexington, MA.

Description

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.